Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Recombinant Protein Market - Insights
Recombinant proteins are used in development of novel therapies for severe chronic diseases such as cancer and other rare diseases. Recombinant protein production requires a special technique known as recombinant DNA (rDNA) technology. Depending on the type of the protein, recombinant proteins are classified into hormones, growth factor, cytokines, plasma protein factor, recombinant metabolic enzymes, and others. Manufacturers such as Biocon, Ltd., Eli, Lilly, and Company, Genentech, Inc., Novo Nordisk Pharmatech A/S, Prospec-Tany Technogene Ltd., Abcam plc, and BPS Bioscience, Inc. offer recombinant proteins for various applications such as drug discovery and development. Advancements in rDNA technology such as Clustered regularly interspaced short palindromic repeats (CRISPR) technique has complemented recombinant protein production. Furthermore, advancements in associated processes such as protein purification methods, alternative expression technologies, development of alternative cell lines, and enhanced cell culture systems have simplified and optimized the recombinant protein production processes.
Increasing research & development expenditure on biologic drugs is expected to boost demand for recombinant proteins for research purposes
Biopharmaceutical organizations are focusing on research and development of novel biosimilars for life threatening diseases such as cardiovascular diseases, cancer, metabolic disorders such as diabetes, and certain rare conditions such as hemophilia. According to Pharmaceutical Research and Manufacturers of America (PhRMA), 2016, member companies invested around US$ 58.8 billion in research and development in 2015, of which, majority was by all biopharmaceutical companies in the U.S. Rare disease medical space holds potential as there is relatively low competition. This is owing to less understanding of the disease progression pathways and entities. Therefore, companies could focus on R&D for development of biologics and subsequently biosimilars in this space. Some of the biosimilars available in the market include Eprex, manufactured by Janssen-Cilag Pty Ltd., which has been successful in treatment of anemia. Demand for biosimilars is increasing significantly, owing to high prices of biologics, in turn leading to high demand for recombinant protein.
The global recombinant protein market was valued at US$ 347.2 million in 2016 and is expected to witness a robust CAGR of 6.2% over the forecast period (2017–2025).
Figure 1. Global Recombinant Protein Market Share, by Application (%) 2017 and 2025
Source: Coherent Market Insights Analysis (2017)
Technological advancement in production of recombinant protein is expected to fuel growth of the recombinant protein market
Advancement in technologies in various areas associated with or facilitating recombinant protein production have supported growth of recombinant protein market. For instance, development of alternative expression technologies such as mammalian cell expression, baculovirus expression, and E.coli expression, development of alternative cell lines, and enhanced cell culture systems have simplified and optimized recombinant protein processes. Furthermore, advanced chromatography protein purification methods such as FPLC and HPLC help in providing highly purified clinical grade recombinant proteins. Clustered regularly interspaced short palindromic repeats (CRISPR) technique is a genome editing technique used to target destruction in human cells and can improve recombinant protein production. Moreover, advancements in bioreactor systems have improved the product’s output within shorter time. According to National Centre for Biotechnology Information (NCBI), in 2014, about 65.6% of clinical scale manufacturers and 42% of commercial manufacturers adopted single use bioreactor for improvement in their bioprocessing.
However, factors such as complex manufacturing process, high costs, and requirement of high quality of these products (responsible for high costs) are expected to hinder growth of the market over the forecast period.
Some major players operating in the recombinant protein market include Crown Bioscience, Inc., ProSpec Tany TechnoGene, Ltd., BPS Bioscience, Inc., Sigma Aldrich Company Ltd., Novoprotein Scientific, PeproTech, Inc., Feldan Bio, Inc., BioVision, Inc., HumanZyme, Inc., and GenScript Biotech Corporation.